Product Center
Ab&B Bio Tech Co., Ltd. JS Has Been Awarded Multiple BioCon Awards for 2022!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-09-09
- Views:
(Summary description)Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech Co., Ltd. JS and its founder, Mr. An Youcai, were respectively awarded the honorary titles of "Most Valuable Biotechnology Enterprise of the Year" and "Outstanding Founder of the Biotechnology Industry of the Year". The double honor fully reflects the high recognition of Ab&B Bio Tech Co., Ltd. JS's achievements in the field of innovative vaccines by the industry!
Ab&B Bio Tech Co., Ltd. JS Has Been Awarded Multiple BioCon Awards for 2022!
(Summary description)Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech Co., Ltd. JS and its founder, Mr. An Youcai, were respectively awarded the honorary titles of "Most Valuable Biotechnology Enterprise of the Year" and "Outstanding Founder of the Biotechnology Industry of the Year". The double honor fully reflects the high recognition of Ab&B Bio Tech Co., Ltd. JS's achievements in the field of innovative vaccines by the industry!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-09-09 16:18
- Views:
Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech Co., Ltd. JS and its founder, Mr. An Youcai, were respectively awarded the honorary titles of "Most Valuable Biotechnology Enterprise of the Year" and "Outstanding Founder of the Biotechnology Industry of the Year". The double honor fully reflects the high recognition of Ab&B Bio Tech Co., Ltd. JS's achievements in the field of innovative vaccines by the industry!
Mr. An Youcai, Chairman/General Manager of Ab&B Bio Tech Co., Ltd. JS, said: "It's a great surprise to receive such an award! Thank you to all the experts, judges, and industry insiders for recognizing Ab&B Bio Tech Co., Ltd. JS. Ab&B Bio Tech Co., Ltd. JS will use this as an incentive to strive to maintain resonance with the national '14th Five-Year Plan' and the national goal of 'expanding and strengthening the bioeconomy.' We will always address the unmet clinical needs of the world, remember the mission of developing global technologically innovative vaccines, let China adopt global innovative vaccines, and let the world use high-quality Chinese vaccines!"
Professor Chen Ze, Vice General Manager/Chief Scientist of Ab&B Bio Tech Co., Ltd. JS, gave a keynote speech: Professor Chen gave a detailed explanation of the development and application of influenza vaccines and unveiled the mysterious veil of the company's first-class new drug product, the quadrivalent influenza virus subunit vaccine. He provided a scientific and detailedly presented analysis of the product advantages, which made everyone look forward to the product's launch!
The road is long and winding, I will search up and down! The company will continue to increase investment in research and development, and strive to develop innovative vaccines. Strive to become the "star power" of biopharmaceuticals, and work together towards the future!
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
